PD Dr. med. Daniel Engeler
Chefarzt
Klinik-/Instituts-/Zentrumsleiter/in
Urologie · Dept. II
Strahlenbelastung des Patienten bei der extrakorporellen Stoßwellen-Lithotripsie
Schwab C, Hobi C, Engeler D, Schmid H. Strahlenbelastung des Patienten bei der extrakorporellen Stoßwellen-Lithotripsie. Journal für Urologie und Urogynäkologie 2010; 17:12-15.
13.03.2010Strahlenbelastung des Patienten bei der extrakorporellen Stoßwellen-Lithotripsie
13.03.2010Journal für Urologie und Urogynäkologie 2010; 17:12-15
Schwab Christoph, Hobi Christian, Engeler Daniel, Schmid Hans-Peter
First experiences with pudendal nerve stimulation in fecal incontinence: a technical report
Bock S, Folie P, Wolff K, Marti L, Engeler D, Hetzer F. First experiences with pudendal nerve stimulation in fecal incontinence: a technical report. Tech Coloproctol 2010; 14:41-4.
01.03.2010First experiences with pudendal nerve stimulation in fecal incontinence: a technical report
01.03.2010Tech Coloproctol 2010; 14:41-4
Bock Susanne, Folie Patrick, Wolff Katja, Marti Lukas, Engeler Daniel, Hetzer F H
IFN-gamma-receptor signaling ameliorates transplant vasculopathy through attenuation of CD8+ T-cell-mediated injury of vascular endothelial cells.
Bolinger B, Engeler D, Krebs P, Miller S, Firner S, Hoffmann M, Palmer D, Restifo N, Tian Y, Clavien P, Ludewig B. IFN-gamma-receptor signaling ameliorates transplant vasculopathy through attenuation of CD8+ T-cell-mediated injury of vascular endothelial cells. Eur J Immunol 2010; 40:733-43.
01.03.2010IFN-gamma-receptor signaling ameliorates transplant vasculopathy through attenuation of CD8+ T-cell-mediated injury of vascular endothelial cells.
01.03.2010Eur J Immunol 2010; 40:733-43
Bolinger Beatrice, Engeler Daniel, Krebs Philippe, Miller Simone, Firner Sonja, Hoffmann Matthias, Palmer Douglas C, Restifo Nicholas P, Tian Yinghua, Clavien Pierre-Alain, Ludewig Burkhard
Bipolar versus monopolar TURP: a prospective controlled study at two urology centers
Engeler D, Schwab C, Neyer M, Grün T, Reissigl A, Schmid H. Bipolar versus monopolar TURP: a prospective controlled study at two urology centers. Prostate Cancer Prostatic Dis 2010
09.02.2010Bipolar versus monopolar TURP: a prospective controlled study at two urology centers
09.02.2010Prostate Cancer Prostatic Dis 2010
Engeler Daniel, Schwab C, Neyer M, Grün T, Reissigl A, Schmid Hans-Peter
Exposure of treating physician to radiation during prostate brachytherapy using iodine-125 seeds: dose measurements on both hands with thermoluminescence dosimeters
Schiefer J, Roth J, Krusche B, Prikler L, Leippold T, Schmid H, Lenggenhager C, Ries G, Plasswilm L, Seelentag W, Vontoggenburg F, Engeler D. Exposure of treating physician to radiation during prostate brachytherapy using iodine-125 seeds: dose measurements on both hands with thermoluminescence dosimeters. Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al] 2009; 185:689-95.
01.10.2009Exposure of treating physician to radiation during prostate brachytherapy using iodine-125 seeds: dose measurements on both hands with thermoluminescence dosimeters
01.10.2009Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al] 2009; 185:689-95
Schiefer Johann, Roth Jakob, Krusche Bernd, Prikler Ladislav, Leippold Thomas, Schmid Hans-Peter, Lenggenhager Cornelius, Ries Gerhard, Plasswilm Ludwig, Seelentag Wolf, Vontoggenburg F, Engeler Daniel
Words of wisdom. Re: Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer
Schmid H, Engeler D. Words of wisdom. Re: Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. European urology 2009; 56:744-5.
01.10.2009Words of wisdom. Re: Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer
01.10.2009European urology 2009; 56:744-5
Schmid Hans-Peter, Engeler Daniel
Re-Implantation after insufficient primary 125-I permanent brachytherapy of prostate cancer [Abstract]
Putora P, Plasswilm L, Seelentag W, Schiefer J, Schmid H, Engeler D (2009). Re-Implantation after insufficient primary 125-I permanent brachytherapy of prostate cancer [Abstract].
01.09.2009Re-Implantation after insufficient primary 125-I permanent brachytherapy of prostate cancer [Abstract]
01.09.2009-
Putora Paul Martin, Plasswilm Ludwig, Seelentag Wolf, Schiefer Johann, Schmid Hans-Peter, Engeler Daniel
EAU Guidelines on Chronic Pelvic Pain
Fall M, Baranowski A, Elneil S, Engeler D, Hughes J, Messelink E, Oberpenning F, de C Williams A. EAU Guidelines on Chronic Pelvic Pain. European urology 2009; 57:35-48.
31.08.2009EAU Guidelines on Chronic Pelvic Pain
31.08.2009European urology 2009; 57:35-48
Fall Magnus, Baranowski Andrew P, Elneil Sohier, Engeler Daniel, Hughes John, Messelink Embert J, Oberpenning Frank, de C Williams Amanda C
Topological methods for the comparison of structures using LDR-brachytherapy of the prostate as an example
Schiefer J, Roth J, Krusche B, Leippold T, Schmid H, Ries G, Plasswilm L, Seelentag W, Vontoggenburg F, Engeler D. Topological methods for the comparison of structures using LDR-brachytherapy of the prostate as an example. Physics in medicine and biology 2009; 54:4959-70.
21.08.2009Topological methods for the comparison of structures using LDR-brachytherapy of the prostate as an example
21.08.2009Physics in medicine and biology 2009; 54:4959-70
Schiefer Johann, Roth J, Krusche B, Leippold T, Schmid Hans-Peter, Ries G, Plasswilm Ludwig, Seelentag Wolf, Vontoggenburg F, Engeler Daniel
The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guérin therapy
Savic S, Casella R, Zellweger T, Forster T, Sulser T, Gasser T, Schönegg R, Spieler P, Dalquen P, Eichenberger T, Mattarelli G, Lehmann K, Schmauss M, Engeler D, Thalmann G, Zlobec I, Bubendorf L. The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guérin therapy. International journal of cancer. Journal international du cancer 2009; 124:2899-904.
15.06.2009The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guérin therapy
15.06.2009International journal of cancer. Journal international du cancer 2009; 124:2899-904
Savic Spasenija, Casella Roberto, Zellweger Tobias, Forster Thomas, Sulser Tullio, Gasser Thomas C, Schönegg René, Spieler Peter, Dalquen Peter, Eichenberger Tobias, Mattarelli Gianfranco, Lehmann Kurt, Schmauss Martina, Engeler Daniel, Thalmann George N, Zlobec Inti, Bubendorf Lukas
Re-Implantation after insufficient primary 125-I permanent brachytherapy of prostate cancer
Putora P, Plasswilm L, Seelentag W, Schiefer J, Schmid H, Engeler D (2009). Re-Implantation after insufficient primary 125-I permanent brachytherapy of prostate cancer.
19.03.2009Re-Implantation after insufficient primary 125-I permanent brachytherapy of prostate cancer
19.03.200913th Annual SASRO Meeting
Putora Paul Martin, Plasswilm Ludwig, Seelentag Wolf, Schiefer Johann, Schmid Hans-Peter, Engeler Daniel
Health-related quality of life after radical prostatectomy and low-dose-rate brachytherapy for localized prostate cancer
Wyler S, Engeler D, Seelentag W, Ries G, Schmid H. Health-related quality of life after radical prostatectomy and low-dose-rate brachytherapy for localized prostate cancer. Urologia internationalis 2009; 82:17-23.
01.01.2009Health-related quality of life after radical prostatectomy and low-dose-rate brachytherapy for localized prostate cancer
01.01.2009Urologia internationalis 2009; 82:17-23
Wyler Stephen Frederic, Engeler Daniel, Seelentag Wolf, Ries Gerhard, Schmid Hans-Peter
Anwendung von Botulinumtoxin Typ A (BoNT-A) bei neurogener Detrusorüberaktivität
Schurch B, Al-Khodairy A, Bersch U, Engeler D, Hugonnet C, Kätterer C, Pannek J. Anwendung von Botulinumtoxin Typ A (BoNT-A) bei neurogener Detrusorüberaktivität. Schweiz Med Forum 2009; 9:284-285.
01.01.2009Anwendung von Botulinumtoxin Typ A (BoNT-A) bei neurogener Detrusorüberaktivität
01.01.2009Schweiz Med Forum 2009; 9:284-285
Schurch Brigitte, Al-Khodairy Abdul-Wahab, Bersch Ulf, Engeler Daniel, Hugonnet C, Kätterer C, Pannek Juergen
Hodentumore und Peniskarzinome
Vontoggenburg F, Engeler D, Schmid H. Hodentumore und Peniskarzinome - Epidemiologie, diagnostische Schritte, Stadieneinteilung, Therapien. Schweiz Zschr Onkologie 2009; 3:18-22.
01.01.2009Hodentumore und Peniskarzinome
01.01.2009Schweiz Zschr Onkologie 2009; 3:18-22
Vontoggenburg F, Engeler Daniel, Schmid Hans-Peter
Guidelines on chronic pelvic pain
Fall M, Baranowski A, Elneil S, Engeler D, Hughes J, Messelink E, Oberpenning F, de C Williams A. Guidelines on chronic pelvic pain. In: European Association of Urology Guidelines Pocket ed. 2009. 2009.
01.01.2009Guidelines on chronic pelvic pain
01.01.2009
Fall Magnus, Baranowski Andrew P, Elneil Sohier, Engeler Daniel, Hughes John, Messelink Embert J, Oberpenning Frank, de C Williams Amanda C
[Urethral fistula due to Crohn's disease: case report of successful conservative management]
Schwab C, Meyer D, Hetzer F, Borovicka J, Schmid H, Engeler D. [Urethral fistula due to Crohn's disease: case report of successful conservative management]. Der Urologe. Ausg. A 2008; 47:1350-2.
01.10.2008[Urethral fistula due to Crohn's disease: case report of successful conservative management]
01.10.2008Der Urologe. Ausg. A 2008; 47:1350-2
Schwab C, Meyer Daniel, Hetzer Franc, Borovicka Jan, Schmid Hans-Peter, Engeler Daniel
[Uro-oncological research from the laboratory and clinical practice]
Engeler D, Ludewig B, Schmid H. [Uro-oncological research from the laboratory and clinical practice]. Der Urologe. Ausg. A 2008; 47:978-81.
01.08.2008[Uro-oncological research from the laboratory and clinical practice]
01.08.2008Der Urologe. Ausg. A 2008; 47:978-81
Engeler Daniel, Ludewig Burkhard, Schmid Hans-Peter
Immunologic ignorance of vascular endothelial cells expressing minor histocompatibility antigen
Bolinger B, Clavien P, Restifo N, Palmer D, Miller S, Scandella E, Engeler D, Tian Y, Krebs P, Ludewig B. Immunologic ignorance of vascular endothelial cells expressing minor histocompatibility antigen. Blood 2008; 111:4588-95.
01.05.2008Immunologic ignorance of vascular endothelial cells expressing minor histocompatibility antigen
01.05.2008Blood 2008; 111:4588-95
Bolinger Beatrice, Clavien Pierre-Alain, Restifo Nicholas P, Palmer Douglas C, Miller Simone, Scandella Elke, Engeler Daniel, Tian Yinghua, Krebs Philippe, Ludewig Burkhard
Feasibility of early intravesical instillation chemotherapy after transurethral resection of the bladder: a prospective evaluation in a consecutive series of 210 cases
Engeler D, Wyler S, Neyer M, Hobi C, Müller J, Schmid H. Feasibility of early intravesical instillation chemotherapy after transurethral resection of the bladder: a prospective evaluation in a consecutive series of 210 cases. Scandinavian journal of urology and nephrology 2008; 42:522-7.
01.01.2008Feasibility of early intravesical instillation chemotherapy after transurethral resection of the bladder: a prospective evaluation in a consecutive series of 210 cases
01.01.2008Scandinavian journal of urology and nephrology 2008; 42:522-7
Engeler Daniel, Wyler Stephen, Neyer Michael, Hobi Christian, Müller Jurg, Schmid Hans-Peter
The ideal analgesic treatment for acute renal colic--theory and practice
Engeler D, Schmid S, Schmid H. The ideal analgesic treatment for acute renal colic--theory and practice. Scandinavian journal of urology and nephrology 2008; 42:137-42.
01.01.2008The ideal analgesic treatment for acute renal colic--theory and practice
01.01.2008Scandinavian journal of urology and nephrology 2008; 42:137-42
Engeler Daniel, Schmid S, Schmid Hans-Peter